BREAKING NEWS: Primmune Therapeutics has just announced an urgent funding boost of $8.6 million in a Series B extension, driving their total financing to $23.3 million. This critical investment will expedite the development of PRTX007, an innovative oral drug aimed at transforming solid tumor immunotherapy.
Based in San Diego, the clinical-stage biotech firm plans to initiate a significant Phase 2 clinical trial in Australia targeting patients with Stage III melanoma that can be surgically removed. The study will explore the efficacy of PRTX007 in conjunction with standard anti-PD-1 therapy, specifically assessing its impact before surgical intervention.
“This financing enables us to rapidly advance PRTX007 into a clearly defined proof-of-principle study with validated efficacy and safety endpoints, with the goal of establishing PRTX007 as a class-leading immunotherapy option for patients with solid tumors,” said Charlie McDermott, CEO and Director of Primmune Therapeutics.
The funding round saw participation from notable investors including Bioqube Ventures, Oberland Capital, and Samsara Biocapital. Primmune Therapeutics, founded in 2017 by James Appleman, Paulo Rangel, and Stephen Webber, focuses on developing novel small molecule toll-like receptor 7 agonists designed to enhance immune responses against cancer while minimizing inflammation—a challenge faced by previous treatments.
PRTX007 has already shown promising results in over 100 healthy volunteers during two Phase 1 clinical studies, demonstrating its ability to elicit the desired immune response without causing significant side effects. This breakthrough has the potential to provide a more effective and less inflammatory treatment option for patients battling solid tumors.
As Primmune Therapeutics moves forward with this pivotal study, the medical community and patients alike are eagerly awaiting results that could redefine cancer treatment protocols. The trial is set to be conducted by Primmune Therapeutics Pty Ltd. in collaboration with Novotech, a leading contract research organization.
The urgency of this development cannot be overstated. With cancer rates rising globally, the need for innovative immunotherapies is more pressing than ever. Keep an eye on this story as it evolves—Primmune Therapeutics is on the verge of potentially changing the landscape of cancer treatment.
Stay tuned for more updates on this groundbreaking advancement in immunotherapy!
